For a long time, Bayer appeared in the price lists marked in red. Recently, however, the color changed: the perennial problem case received strong tailwinds. Over a three-month period, Bayer shares gained nearly two thirds, outshining all other DAX members. The rally can be traced back to three solid catalysts: a third quarter 2025 that exceeded market expectations operationally, a surprisingly favorable stance by the US government in the Roundup complex, and positive pipeline and regulatory news. Altogether, this fits perfectly into the picture of an accelerating \u201cde-risking\u201d phase \u2013 not because risks are disappearing, but because they suddenly appear more predictable. The scientifically most important price driver is called \u201cAsundexian.\u201d Final study data showed that the blood thinner reduces the risk of a recurrent stroke by 26% without increasing bleeding risk. The company therefore reaffirmed the drug\u2019s blockbuster potential, implying possible annual sales of more than EUR 1 billion. According to management, it is still too early for a precise revenue estimate, as the exact approval conditions and pricing negotiations must first be clarified. However, Bayer is already examining additional indications for the active ingredient. This is an important development, as several of the group\u2019s key revenue drivers are facing increasing pressure from generic competition.<\/p>\n\n